Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
10.05
-0.15 (-1.47%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Daxor Revenue
Daxor had revenue of $23.02K in the half year ending June 30, 2026, a decrease of -67.92%. This brings the company's revenue in the last twelve months to $31.36K, down -52.70% year-over-year. In the year 2025, Daxor had annual revenue of $26.69K, down -77.71%. That makes Daxor the 46,837th largest company in the world by revenue and 7,047th in the United States.
Revenue (ttm)
$31.36K
Revenue Growth
-52.70%
P/S Ratio
1,870.99
Revenue / Employee
$697
Employees
45
Market Cap
58.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.69K | -93.03K | -77.71% |
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | 380.14K | -49.82K | -11.59% |
| Dec 31, 2018 | 429.96K | -121.46K | -22.03% |
| Dec 31, 2017 | 551.42K | 17.80K | 3.34% |
| Dec 31, 2016 | 533.62K | -514.37K | -49.08% |
| Dec 31, 2015 | 1.05M | -564.57K | -35.01% |
| Dec 31, 2014 | 1.61M | -434.97K | -21.24% |
| Dec 31, 2013 | 2.05M | -350.04K | -14.60% |
| Dec 31, 2012 | 2.40M | 316.37K | 15.20% |
| Dec 31, 2011 | 2.08M | -95.50K | -4.39% |
| Dec 31, 2010 | 2.18M | -609.16K | -21.87% |
| Dec 31, 2009 | 2.79M | 411.46K | 17.33% |
| Dec 31, 2008 | 2.37M | 141.01K | 6.31% |
| Dec 31, 2007 | 2.23M | 309.75K | 16.10% |
| Dec 31, 2006 | 1.92M | -306.00K | -13.72% |
| Dec 31, 2005 | 2.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.81M |
| Pro-Dex | 77.55M |
| KORU Medical Systems | 45.11M |
| Retractable Technologies | 33.90M |
| Precision Optics Corporation | 31.53M |
| Bionano Genomics | 30.18M |
| Stereotaxis | 30.07M |
| Nephros | 20.72M |
DXR News
- 3 days ago - Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 - GlobeNewsWire
- 4 days ago - Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 - GlobeNewsWire
- 5 days ago - Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 - GlobeNewsWire
- 17 days ago - Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 - GlobeNewsWire
- 5 weeks ago - Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference - GlobeNewsWire
- 6 weeks ago - Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - GlobeNewsWire
- 7 weeks ago - Daxor Quarterly report: Q2 2026 - Filings
- 2 months ago - Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas - GlobeNewsWire